Who we are
BioSpeedia is a biotechnology company specializing in the development and production of rapid diagnostic tests for infectious diseases.
It was founded in 2011 by two scientists from the Institut Pasteur : Evelyne Begaud and Yves Germani. The Institut Pasteur, created in 1888, is the first non-profit foundation and is the source of 10 Nobel Prizes. Evelyne Begaud is the current president of BioSpeedia, and Yves Germani is its chief scientific officer.
In connection with the Covid-19 pandemic and the implementation of regular screenings with the use of antigenic tests, BioSpeedia has signed a strategic and technological partnership with SICPA to offer services allowing safe travel in addition to our range of screening products.
Still in connection with the production of antigenic tests for the detection of Covid-19 infection, an industrial partnership has also been signed with Delpharm Biotech, which manufactures our rapid test in France. We have a fully automated French production line for “lateral flow” tests.
Sales and worldwide distribution of BioSpeedia, product registration, liaison with regulatory authorities, logistics and shipping are handled by our distribution arm BioVitess Ltd., a sister company based in the UK.
BioSpeedia also has subsidiaries in the United States with BioSpeedia LLC and in Switzerland with BioSpeedia International SARL.
We are a spin-off from Institut Pasteur and have a license giving us access to the main reagents.
- Founded in 2011
The establishment of BioSpeedia
After spending 3 decades at Institut Pasteur, Yves Germani and Evelyne Begaud, establish the Company as the official spin-off from the premier French Institute.
Grant from Aide au Partenariat Technologique
Developed fast and accurate lateral flow diagnostic kit to detect Neisseria meningitidis
Developed a diagnostic kit to rapidly detect bacterial meningitis using spinal fluid and subsequently using urine samples.
Received CE Mark for our SARS-CoV-2 rapid antibody test kit
COVID19SEROSpeed-IgM-IgG Test is an immunochromatographic assay designed for the qualitative detection and differentiation of specific IgM and IgG antibodies to SARS-CoV-2 coronavirus in human fingertip blood samples
Seal of Excellence from H2020
For COVID-19 Response
Received CE Mark for our SARS-CoV-2 rapid antigen test kit
Covid-19Speed-Antigen Test is a colloidal gold enhanced double antibody sandwich immunoassay for qualitative determination of SARS-CoV-2 antigen in nasopharyngeal swabs.
Received CE mark for our Covid-19 self-test kits
BioSpeedia COVID19 Nasal AUTOTEST and BioSpeedia® Autotest COVID-19 tests are intended to detect a specific antigen of SARS-CoV-2 in a nasal swab sample. These are self-tests, so they can be used by the patients themselves.